A Phase 1/2 interventional study of AProArt-CD34 and CliniMACS® CD34 Reagent System cell sorter device in Severe Combined Immunodeficiency, sponsored by University of California, San Francisco. Recruiting at 1 site in United States. Open to participants aged 2 Months and older. Per ClinicalTrials.gov, last updated 2026-02-13.
Sponsored by University of California, San Francisco · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies in Severe Combined Immunodeficiency with a site in United States — 9 open to participants now, 11 under way, none of them phase 3. Severe Combined Immunodeficiency · United States.
Among the 38 studies in Severe Combined Immunodeficiency with a site in United States, this one is the 8th largest by planned enrollment of the 24 interventional ones that give a count, is one of 2 that started in 2018, is one of 8 in phase 1/2, and was the 33rd registered.
59 studies on the registry are indexed under Severe Combined Immunodeficiency; 14 are open to participants now.
Browse Severe Combined Immunodeficiency studies →9 of the 38 studies in Severe Combined Immunodeficiency with a site in United States are open now. Recruiting first, the newest first:
Paul Szabolcs · Sites in United States
Ages 5–40
Paul Szabolcs · Sites in United States
Ages 2 mo–60 yrs
Paul Szabolcs · Sites in United States
Ages 2 mo–55 yrs
National Heart, Lung, and Blood Institute (NHLBI) · Sites in United States
Ages 6 mo–99 yrs
University of California, Los Angeles · Sites in United States, United Kingdom
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 7 Severe Combined Immunodeficiency studies recruiting now, 2 set no upper age limit and 4 stop at 75 or younger; 6 take children under 18; 1 takes healthy volunteers.
This study: 2 Months and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 16 · Phase 3 3
First in 1990; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 24 is above the median of 10 across 31 interventional studies indexed under Severe Combined Immunodeficiency.
Median enrollment 9 across the 24 interventional studies, 88 across the 12 observational. Of the 24 that completed or were terminated, 10 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 38 have an industry lead sponsor. The 10 most frequent:
University of California, San Francisco is the lead sponsor of 2,172 studies on the registry; 370 are open to participants now.
Of its 269 completed or terminated interventional studies of FDA-regulated products, 203 (75%) have results posted.
University of California, San Francisco has 4 studies filed under Severe Combined Immunodeficiency — fewer than ten, so there is no comparison to draw.
3 of the studies in Severe Combined Immunodeficiency with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01852370Paul SzabolcsSequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency Diseases | 2026-11 |
| NCT01962415Paul SzabolcsReduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT | 2026-11 |
| NCT03597594St. Jude Children's Research HospitalHaplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID) | 2027-07-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 38 studies in Severe Combined Immunodeficiency with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to determine if a new method can be used to treat Artemis-deficient Severe Combined Immunodeficiency (ART-SCID), a severe form of primary immunodeficiency caused by mutations in the DCLRE1C gene. This method involves transferring a normal copy of the DCLRE1C gene into stem cells of an affected patient. Participants will receive an infusion of stem cells transduced with a self-inactivating lentiviral vector that contains a normal copy of the DCLRE1C gene. Prior to the infusion they will receive sub-ablative, dose-targeted busulfan conditioning. The study will investigate if the procedure is safe, whether it can be done according to the methods described in the protocol, and whether the procedure will provide a normal immune system for the patient. A total of 24 newly diagnosed patients will be enrolled at the University of California San Francisco in this single-site trial and will be followed for 15 years post-infusion. It is hoped that this type of gene transfer may offer improved outcomes for ART-SCID patients who lack a brother or sister who can be used as a donor for stem cell transplantation or who have failed to develop a functioning immune system after a previous stem cell transplant.
Children with SCID generally do not survive beyond the first year of life without definitive treatment. The most effective current cure is hematopoietic stem cell transplant (HCT) with a human leukocyte antigen (HLA) matched sibling. While a matched sibling HCT can successfully treat ART-SCID, fewer than 20% of affected children have such a donor, and even when a matched sibling donor is available there is often incomplete T and B cell immune reconstitution. ART-SCID is the most difficult type of SCID to cure by hematopoietic stem cell transplant using alternative donors. Engraftment typically requires intensive conditioning with high dose alkylating agents to prevent rejection and to open marrow niches. These patients also have a high risk of developing graft versus host disease (GVHD) when alternative donors are used. The great majority of patients have absent B cell reconstitution and require lifelong administration of immunoglobulin infusions. Patients with ART-SCID who do receive high doses of alkylators, especially when 2 agents are used, have poorer survival, abnormal dental development, endocrinopathies, and short stature in comparison with children exposed to no or limited alkylators or children with SCID types that are not associated with a DNA repair defect. For these reasons, a safer, more effective approach to curing ART-SCID is needed. Autologous gene-corrected hematopoeitic stem cell transplant may eliminate both the risk of GVHD and the need for alkylators to prevent rejection.
The study design is a single-cohort, longitudinal experiment using non-randomized patients treated once with a lentiviral vector for gene-correction of Artemis-deficient SCID after conditioning with low-dose busulfan. No formal control group is planned for gauging safety; rather, intensive monitoring of the initial 6 enrollees was undertaken to preclude continued accrual in the presence of safety signals. This enrollment stage was completed in 2019 with no safety signals identified, and long-term safety will be monitored for 15 years. Bone marrow stem cells will be harvested from participants, and CD34 cells will be isolated using the CliniMACS® CD34 Reagent System cell sorter device. The CD34 cells will be transduced with the AProArt lentiviral vector, and cryopreserved. Aliquots of the cells will undergo safety testing and be reserved for potency evaluation. All patients will receive busulfan conditioning targeted over 2 days to achieve a cumulative area under the curve (AUC) of 20 mg*hr/L (an ablative cumulative AUC is 60-90mg*hr/L).
Following the infusion of AProArt-transduced cells, patients will be assessed weekly through 12 weeks post-transplant and at week 16, monthly through month 6 post-transplant, every 3 months through month 24, every 6 months during years 2-5, and then annually through year 15. Assessments will include physical examination, clinical laboratory tests, collection of specimens for research studies, and completion of Quality of Life questionnaires. Neurodevelopmental testing will be performed at age-appropriate time points.
At weeks 4, 6, 8, 12, 16, and 24, research specimens will be evaluated for evidence of gene transduced peripheral blood mononuclear cells and when possible, cell lineages including T, B, NK and granulocyte/myeloid cells. If there is no evidence of gene transduced cells at 6 weeks (42 days) post infusion, planning for an alternative treatment will begin, with the final decision regarding further therapy to be based on gene-marking results at 10 weeks.
If the absolute neutrophil count is \< 200/µl or platelets \< 20,000/µl on 3 independent determinations after day 42 post infusion of transduced cells, the patient may receive an allogeneic hematopoeitic stem cell transplant. Patients who were neutropenic prior to conditioning (SCID-related neutropenia) but responsive to granulocyte-colony stimulating factor (GCSF) will not be considered to have failed, provided the absolute neutrophil count can be maintained above >300/µl with GCSF.
Recipients will be followed for toxicity and durable reconstitution of T and B cell immunity. Immune reconstitution of T cells will be monitored on a regular basis. Patients with evidence of clinically inadequate immune reconstitution, low vector copy number (VCN), or any other features suggesting clinically inadequate response to the initial gene therapy procedure will be offered a repeat infusion of gene-transduced cells. Conditioning regimens given prior to a repeat gene therapy procedure may include low-dose busulfan, other conditioning, or no conditioning.
Historical controls who received alternative donor allogeneic transplants as treatment for ART-SCID will serve as the comparator arm for secondary endpoints.
An independent Data Safety Monitoring Board (DSMB) has been appointed for safety monitoring of this trial. The DSMB reviews all data for safety on a regular schedule, based on numbers of enrolled subjects and conducts special urgent review of any protocol related Serious Adverse Events (SAE). In the early stage of the trial, the DSMB reviewed results of each of the first 3 cases prior to proceeding with subsequent patients.
The investigational product (IND17711) for the ART-SCID gene transfer study is not available for expanded access use. As per 21 CFR Part 312.305(3), the study management team has determined that providing the investigational product for expanded access use at this time would interfere with the conduct and completion of the clinical trial and potential development of future expanded access use. The investigational product is available to eligible patients through participation in this clinical trial.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Gene Transfer for Artemis-Deficient Severe Combined Immunodeficiency (ART-SCID) Using a Self-Inactivating Lentiviral Vector (AProArt) to Transduce Autologous CD34 Hematopoietic Cells. The CliniMACS® CD34 Reagent System sorter device will be used to select CD34 cells. Patients will be conditioned with low dose busulfan prior to transplant.
Drug: AProArt-CD34 · Device: CliniMACS® CD34 Reagent System cell sorter device · Drug: Busulfan
Participants will undergo infusion with autologous hematopoietic cells transduced with a lentiviral vector, AProArt, which contains the correct form of DCLRE1C complementary deoxyribonucleic acid DNA, after receiving sub-ablative, exposure-targeted busulfan conditioning.
Also known as: lentiviral gene therapy using AProArt
Processing of hematopoietic progenitor cells to select CD34 cells, using the CliniMACS® CD34 Reagent System, prior to infusion.
Busulfan is a cell cycle non-specific alkylating antineoplastic agent, in the class of alkyl sulfonates. Patients will receive low-dose busulfan conditioning targeted over 2 days to achieve a cumulative area under the curve (AUC) of 20 mg\*hr/L.
Also known as: Busulfex
To demonstrate that ART-SCID patients receiving AProArt-CD34 infusion have superior overall survival (OS) at 24 months post treatment with AProArt-CD34 versus the established outcome of 0% OS for patients who receive no treatment for ART-SCID
Patient survival status and (if applicable) cause of death will be recorded to assess overall survival.
Time frame: 24 months
B cell immune reconstitution by 24±2 months compared with historical control cohort of allogeneic transplant recipients
B cell immune reconstitution will be defined as cessation of immunoglobulin replacement therapy
Time frame: 24 months
Number of participants with T cell immune reconstitution compared with historical controls who received allogeneic transplants to treat ART-SCID.
T cell immune reconstitution will be defined as presence of both of the following: 1) a. CD3\>1000/mm3; 2) CD4\>500/mm3.
Time frame: 24 months
Event Free Survival
Events are defined as death, use of a repeat infusion of gene-corrected cells to enhance T/B cell immune reconstitution or requirement for performance of an allogeneic HCT.
Time frame: 24 months
Adverse event (AE) profile associated with the study intervention from treatment through 15 years after the gene transfer procedure
Clinical and laboratory AEs as measured by CTCAE V4
Time frame: 15 years
Number of participants with B cell reconstitution beyond 24 months, including B cell numbers and function
B cell reconstitution will be defined as presence of at least two of the following: 1) B cell number \>40/mm3; 2) Cessation of immunoglobulin replacement therapy; 3) Protective specific antibody responses. The number of participants who meet the definition for B cell reconstitution will be tabulated.
Time frame: 15 years
Efficacy of targeting low exposure busulfan in infants and children, calculated by percentage of participants whose treatment meets study parameters using a validated population pharmacokinetic model to calculate individualized busulfan clearance.
Achievement of final target cumulative AUC of 20±2 mg\*hr/L in approximately 90% of subjects
Time frame: 42 days
Repertoire diversity of T and B cells, as assessed by analyzing T cell receptor gene variable beta sequence (TCR-Vb) and immunoglobulin heavy chain (IGH) rearranged receptors and calculating diversity Shannon Index.
Measured by deep sequencing of the T cell receptor (TCR) gene variable beta sequence (TCR-Vb) and immunoglobulin heavy chain (IGH) rearranged receptors. The diversity Shannon Index is expected to be above 7.5 by 24±2 months post treatment in 90% of patients.
Time frame: 24 months
Determine if B cell receptor diversity at 6 months is predictive of B cell reconstitution over 15 years by analyzing B cell receptor gene variable beta sequence and immunoglobulin heavy chain rearranged receptors and calculating diversity Shannon Index.
A Shannon Index \>5 is expected to be a biomarker for B cell reconstitution. B cell receptor diversity will be measured throughout study participation.
Time frame: 15 years
Determine if at 6 months T cell receptor (TCR) diversity and/or absolute CD3, CD4, naïve CD4 counts predict T cell reconstitution at 24 months or need for 2nd treatment throughout the 15 year follow-up period.
TCR-Vb diversity and absolute CD3, CD4 and naïve CD4 counts will be measured at 6 months. T cell reconstitution will be measured throughout study participation.
Time frame: 15 years
Stability of mean vector copy number (VCN) and the location of vector integration sites in sorted T, B, and natural killer (NK) cells, granulocytes and monocytes in peripheral blood over time after infusion of transduced HSC.
Mean vector copy number (VCN) and the location of vector integration sites will be measured at 6±1, 12±1 and 24±2 months and then annually through 15 years after infusion of AProArt-CD34. The mean VCN should be \>0.5 copies/cell in T and B cells and \>0.01 in NK, myeloid and granulocytes by 24±2 months post treatment.
Time frame: 24 months
Characterization of insertion sites in multiple cell lineages as an indicator of diversity, multilineage engraftment, and tabulation of any clonal expansion that might indicate development of a malignancy.
Insertion sites will be measured at 6±1, 12±1, 24±2 months, and annually through 15 years after infusion of AProArt-CD34. Cell insertion sites are expected to be diverse with no clone representing \>20% of a lineage at 24 months.
Time frame: 24 months
Potential benefit of prophylactic sirolimus in reducing the incidence of transient autoimmune hemolytic anemia (AIHA) post infusion of AProArt-CD34, as assessed by number of participants with clinical diagnosis of AIHA.
Incidence of autoimmune hemolytic anemia by 24±2 months post infusion following administration of prophylactic sirolimus, as assessed by monitoring of hemoglobin, direct and indirect Coombs, reticulocyte, and lactate dehydrogenase results. Incidence of AIHA requiring treatment is expected to be \<40% of patients on prophylactic sirolimus.
Time frame: 24 months
Measurement of radiation sensitivity in peripheral blood NK cells for development and validation of a rapid functional assay for radiation-sensitive SCID.
Development and validation of an assay for radiation sensitive SCID in peripheral blood NK cells
Time frame: 24 months
Potency of AProArt-CD34 as indicated by capacity for in vitro differentiation of participant specimens into T cells and assessment of average VCN as a surrogate marker for potency.
Demonstration that post-transduction patient CD34+ cells have the capacity for in vitro differentiation into T cells and that average VCN is a surrogate marker for potency. One or more potency assays will be developed and validated for AProArt-transduced CD34+ HSC that give results within 52 days of transduction, and correlation of these with VCN obtained at 6 and 14 days post transduction with AProArt.
Time frame: 5 years
Hematopoietic recovery in patients with ART-SCID who receive self-inactivating (SIN) lentiviral vector (AProArt)-transduced CD34 cells through a repeat infusion autologous stem cell transplant.
Patients will undergo blood tests to measure complete blood count and differential following a repeat infusion of gene corrected cells.
Time frame: 5 years
Effects of targeted low exposure busulfan conditioning on patient growth/stature
Patient height (cm) and weight (kg) will be measured and compared with norms for age
Time frame: 5 years
Effects of busulfan on patient dental development
Dental histories and clinical notes will be reviewed to compare permanent tooth development will be compared with development norms for age from age 5 through age 15 years
Time frame: 5 years
Patient reported outcome of undergoing treatment with gene-corrected cells as assessed by the PedsQL questionnaires.
Age-appropriate Pediatric Quality of Life Inventory (PedsQL) questionnaires will be administered at baseline and years 1, 2, 4, 8, 10, 12, and 15. Four domains (Physical Functioning, Emotional Functioning, Social Functioning, and School Functioning) are reverse-scored on a 5-point Likert scale and transformed to a 0-100 scale, with higher scores indicating better outcomes.
Time frame: 5 years
Family impact of undergoing treatment with gene-corrected cells.
The Pediatric Quality of Life Inventory (PedsQL) Family Impact module will be administered at baseline and years 1, 2, 4, 8, 10, 12, and 15. Responses are indicated on a 5-point Likert scale and transformed to a 0-100 scale, with higher scores indicating better outcomes.
Time frame: 15 years
Effects of the study intervention on neurodevelopment over time
Neurodevelopment will be assessed at ages 3, 5, 8, 11, 14 and 17 years using applicable age-appropriate instruments (Vineland Adaptive Behavior Scales, Behavior Rating Inventory of Executive Functioning, Behavioral Assessment for Children, Bayley Scales of Infant Development, Wechsler Intelligence Scales, California Verbal Learning Test, Conners Continuous Performance Test, Delis-Kaplan Executive Function System, and Wide Range Achievement Test). Results will be compared with norms for ages 18 months and ages 3, 5, 8, 11, 14 and 17 years.
Time frame: 5 years
Plan to share: Yes — Individual participant data that underlie the results reported in scientific journals (text, tables, figures, and appendices) after de-identification.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Beginning 3 months and ending 5 years following article publication
Access criteria: Researchers can submit a request for access to the study Steering Committee. If the proposal is determined to be methodologically sound, data requestors will need to sign a data access agreement prior to gaining access.
Started May 2018 (actual). Primary completion is estimated for Jun 2038, 241 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Busulfan
Severe Combined Immunodeficiency →
University of California, San Francisco →